Test Price
2,800 AED✅ Home Collection Available
SPAG1 Gene Primary Ciliary Dyskinesia Type 28 Genetic Test in UAE – 2800 AED
Executive Summary & Core Metrics
This SPAG1 gene NGS test delivers 99.9% diagnostic sensitivity through ISO 9001:2015 accredited processing, ensuring precise identification of primary ciliary dyskinesia type 28 in a single blood draw. Your test includes paid hospital‑grade home collection via ISO‑certified cold‑chain logistics, VIP mobile phlebotomy (8 AM–11 PM), direct insurance billing verification by WhatsApp (+971 54 548 8731), and post‑test telephonic clinical guidance from a DHA‑licensed physician.
Test Overview & Methodology
The SPAG1 gene test uses Next‑Generation Sequencing (NGS) to detect pathogenic variants responsible for primary ciliary dyskinesia type 28, a congenital disorder of motile cilia that causes chronic sinopulmonary infections.
| Aspect | Our SPAG1 NGS Test | Sanger Sequencing (Alternative) |
|---|---|---|
| Precision | Full gene coverage with deep intronic and copy‑number variant analysis | Limited to coding exons, may miss regulatory or deep intronic mutations |
| Methodology | NGS (Illumina® platform, ISO‑validated bioinformatics) | Capillary electrophoresis (older, lower throughput) |
| Turnaround Time | 3–4 weeks | 4–6 weeks |
| Price (AED) | 2,800 | 2,400–2,600 |
Physician Insight & Safety Protocols
“This NGS test offers a definitive molecular diagnosis for primary ciliary dyskinesia, but I always correlate results with clinical signs like recurrent otitis, neonatal respiratory distress, and situs abnormalities. A negative finding does not exclude PCD caused by other genes, so please continue your prescribed therapies and follow‑up with your ENT specialist.” — Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Safety & Clinical Exclusion
⚠️ Important Safety Notice
Do not discontinue any prescribed medication (e.g., antibiotics, bronchodilators, mucolytics) without explicit instruction from your treating physician.
- Exclusion Criteria: Inability to provide a blood sample; current severe thrombocytopenia or uncorrected coagulopathy; blood transfusion within the previous 72 hours (may interfere with cell‑free DNA analysis if applicable).
- Emergency Red Flags: If you develop sudden shortness of breath, chest pain, high fever (>39 °C), or confusion, seek immediate emergency care – these are unrelated to the blood draw and may indicate a respiratory exacerbation.
Patient FAQ & Clinical Guidance
1. How accurate is the SPAG1 NGS test for diagnosing primary ciliary dyskinesia type 28?
Our SPAG1 gene test achieves over 99.9% analytical sensitivity for detecting single nucleotide variants and copy‑number changes within the SPAG1 gene. The NGS technology used covers all coding exons and flanking intronic regions, validated against international reference standards. However, a negative result does not eliminate the possibility of other PCD‑causing genes; your doctor may recommend a comprehensive panel.
2. What sample is needed, and how does home collection work in the UAE?
We require a single blood sample (3–5 mL in an EDTA tube) or a dried blood spot on an FTA card, collected by a DHA‑licensed phlebotomist at your doorstep. Our team arrives in a temperature‑controlled vehicle between 8 AM and 11 PM, verifies insurance eligibility via WhatsApp (+971 54 548 8731) before the draw, and transports the sample in a cold‑chain container to our ISO‑certified laboratory. You receive a digital tracking number immediately.
3. What if my result is positive? Who explains the implications for me and my family?
A positive SPAG1 variant indicates autosomal recessive primary ciliary dyskinesia type 28, and our included post‑ clinical guidance connects you with a DHA genetic counsellor to interpret the finding and discuss family screening. You will also receive a detailed laboratory report with clinical recommendations for your ENT physician. Because PCD can affect siblings, we strongly advise genetic counselling for family members at risk.
UAE Regulatory & Data Privacy Adherence
This test is performed under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Our facility holds ISO 9001:2015 certification (INT/EGQ/2509DA/3139) and DHA molecular genetics license. Patient consent adheres to Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | SPAG1 Gene Primary Ciliary Dyskinesia Type 28 Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral whole blood (EDTA tube) or dried blood spot (FTA card) |
| Methodology Used | Next‑Generation Sequencing (NGS) – Illumina® platform |
| ICD-10-CM Code | Q34.8 |
| LOINC Code | 56744-3 |
| DHA Facility License & Laboratory Address | DHA License 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians